// App-Quantinova.ai

: ATIM-33. INTERIM RESULTS OF A PHASE II MULTI-CENTER STUDY OF ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

Researchers

Presenter

  • Shirley Ong

Principal Investigators

  • Rohan Ramakrishna

  • Adam Sonabend

  • Michael Vogelbaum

  • Gelareh Zadeh

  • Laura Agensky

  • Carin Bidwell

  • Barry Watkins

  • Frank Tufaro

  • Joanna Peterkin

Medical Centers

  • New York Presbyterian Weill Cornell Medical Center, New York, NY

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Lee Moffitt Cancer Center, Tampa, FL, USA

  • DNAtrix, Inc., Houston, TX

  • DNAtrix, Inc., Houston, TX

Locations

  • United States

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Delta-24-RGD-4C

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved